Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: 36-month analysis of the illuminate-a trial

AMERICAN JOURNAL OF KIDNEY DISEASES(2023)

引用 0|浏览14
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要